Wall Bradley A, Galvão Daniel A, Fatehee Naeem, Taaffe Dennis R, Spry Nigel, Joseph David, Newton Robert U
School of Psychology and Exercise Science, Murdoch University, Murdoch, WA 6150, Australia ; Exercise Medicine Research Institute, Edith Cowan University, Joondalup, WA 6027, Australia.
Exercise Medicine Research Institute, Edith Cowan University, Joondalup, WA 6027, Australia.
Adv Urol. 2015;2015:976235. doi: 10.1155/2015/976235. Epub 2015 Oct 26.
Objectives. To investigate if androgen deprivation therapy exposure is associated with additional risk factors for cardiovascular disease and metabolic treatment-related toxicities. Methods. One hundred and seven men (42-89 years) with prostate cancer undergoing androgen deprivation therapy completed a maximal graded objective exercise test to determine maximal oxygen uptake, assessments for resting metabolic rate, body composition, blood pressure and arterial stiffness, and blood biomarker analysis. A cross-sectional analysis was undertaken to investigate the potential impact of therapy exposure with participants stratified into two groups according to duration of androgen deprivation therapy (<3 months and ≥3 months). Results. Maximal oxygen uptake (26.1 ± 6.0 mL/kg/min versus 23.2 ± 5.8 mL/kg/min, p = 0.020) and resting metabolic rate (1795 ± 256 kcal/d versus 1647 ± 236 kcal/d, p = 0.005) were significantly higher in those with shorter exposure to androgen deprivation. There were no differences between groups for peripheral and central blood pressure, arterial stiffness, or metabolic profile. Conclusion. Three months or longer exposure to androgen deprivation therapy was associated with reduced cardiorespiratory capacity and resting metabolic rate, but not in a range of blood biomarkers. These findings suggest that prolonged exposure to androgen deprivation therapy is associated with negative alterations in cardiovascular outcomes. Trial registry is: ACTRN12609000200280.
目的。研究雄激素剥夺疗法的暴露是否与心血管疾病的额外危险因素及代谢治疗相关毒性有关。方法。107名接受雄激素剥夺疗法的前列腺癌男性患者（42 - 89岁）完成了一项最大分级目标运动测试，以确定最大摄氧量，进行静息代谢率、身体成分、血压和动脉僵硬度评估以及血液生物标志物分析。进行横断面分析，根据雄激素剥夺疗法的持续时间（<3个月和≥3个月）将参与者分为两组，以研究治疗暴露的潜在影响。结果。雄激素剥夺暴露时间较短者的最大摄氧量（26.1±6.0 mL/kg/min对23.2±5.8 mL/kg/min，p = 0.020）和静息代谢率（1795±256 kcal/d对1647±236 kcal/d，p = 0.005）显著更高。两组在外周和中心血压、动脉僵硬度或代谢谱方面无差异。结论。暴露于雄激素剥夺疗法三个月或更长时间与心肺功能和静息代谢率降低有关，但在一系列血液生物标志物方面并非如此。这些发现表明，长期暴露于雄激素剥夺疗法与心血管结局的负面改变有关。试验注册号为：ACTRN12609000200280。
